Event-Driven Stocks

Trius Therapeutics Inc

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

Signs2 good3 warningdetails ↓

Financials

SEC XBRL · annual
 FY12FY11FY10FY09
Revenue$9.8M$2.7M$8.0M$5.0M
Operating income−$57.2M−$19.8M−$20.7M−$22.2M
Net income−$53.9M−$18.3M−$23.9M−$22.7M
Total assets$75.3M$68.1M$49.5M
Total liabilities
Equity$56.8M$49.9M$45.5M−$51.5M
EPS (diluted)$-0.22$-0.43$-2.36
Shares out.38.6M28.7M23.6M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2012
Operating margin
−582.1%
Net margin
−548.5%
Return on equity
−95.0%
Return on assets
−71.6%
Return on capital (ROCE)
−100.8%
Liabilities / assets
Debt / equity
Book value / share
$1.47
Revenue growth (YoY)
262.1%
Net income growth (YoY)

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2012
Accruals / assets
5.9%clean
Piotroski F-Score
4/8mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
60
/ 100
Profitability 0Growth 100Catalyst 33Earnings quality 67Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

3 warning2 good
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Revenue is growing year-over-year
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Insider transactions

SEC Form 4 · most recent
0 acquisitions10 disposalsnet 487,843 shares · last 10
InsiderDateTypeSharesPrice
Finn JohnOfficer — Chief Scientific OfficerSep 11, 2013D3,230
Eastham KarinDirectorSep 11, 2013D6,000
O'Leary BrendanDirectorSep 11, 2013D21,302
Schmid John P.Officer — Chief Financial OfficerSep 11, 2013D107,639
Truex Paul FDirectorSep 11, 2013D11,270
Bartizal KenOfficer — Chief Development OfficerSep 11, 2013D96,400
Prokocimer PhilippeOfficer — Chief Medical OfficerSep 11, 2013D12,190
Morneau MichaelOfficer — VP Finance &amp; CAOSep 11, 2013D14,070
Stein JeffreyOfficer — President &amp; CEOSep 11, 2013D210,457
Kabakoff David SDirectorSep 11, 2013D5,285

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)